Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kunwei Shen

Showing results (31-40 of 207) with videos related to

Pageof 21
Sort By:
Journal of Geriatric Oncology|November 10, 2019
Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancerYufei Zeng, Weiqi Gao, Lin Lin, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|February 9, 2017
Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT studyXiaosong Chen, Guolin Ye, Chenfang Zhang, et al.
Cancer Science|November 1, 2011
Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancerXiaosong Chen, Jiayi Wu, Hongfen Lu, et al.
Translational Oncology|November 3, 2017
A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast CancerGen Wang, Xiaosong Chen, Yue Liang, et al.
Breast Cancer Research and Treatment|August 3, 2020
Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysisWeiqi Gao, Yufei Zeng, Xiaochun Fei, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 1, 2010
An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancerWen Chen, Zefei Jiang, Zhimin Shao, et al.
Cancer Science|August 13, 2010
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cellsChuandong Ma, Xiuqing Niu, Jianmin Luo, et al.
Therapeutic Advances in Medical Oncology|June 20, 2020
A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancerZheng Wang, Hui Wang, Xinyuan Ding, et al.
Breast Cancer Research and Treatment|September 8, 2022
Axilla lymph node dissection can be safely omitted in patients with 1-2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysisWeiqi Gao, Shuangshuang Lu, Yufei Zeng, et al.
Cancers|September 9, 2022
Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast CancerLan Shu, Yiwei Tong, Zhuoxuan Li, et al.
Pageof 21

Showing results (31-40 of 207) with videos related to

Sort By:
Pageof 21
Journal of Geriatric Oncology|November 10, 2019
Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancerYufei Zeng, Weiqi Gao, Lin Lin, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|February 9, 2017
Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT studyXiaosong Chen, Guolin Ye, Chenfang Zhang, et al.
Cancer Science|November 1, 2011
Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancerXiaosong Chen, Jiayi Wu, Hongfen Lu, et al.
Translational Oncology|November 3, 2017
A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast CancerGen Wang, Xiaosong Chen, Yue Liang, et al.
Breast Cancer Research and Treatment|August 3, 2020
Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysisWeiqi Gao, Yufei Zeng, Xiaochun Fei, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 1, 2010
An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancerWen Chen, Zefei Jiang, Zhimin Shao, et al.
Cancer Science|August 13, 2010
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cellsChuandong Ma, Xiuqing Niu, Jianmin Luo, et al.
Therapeutic Advances in Medical Oncology|June 20, 2020
A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancerZheng Wang, Hui Wang, Xinyuan Ding, et al.
Breast Cancer Research and Treatment|September 8, 2022
Axilla lymph node dissection can be safely omitted in patients with 1-2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysisWeiqi Gao, Shuangshuang Lu, Yufei Zeng, et al.
Cancers|September 9, 2022
Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast CancerLan Shu, Yiwei Tong, Zhuoxuan Li, et al.
Pageof 21